b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...

7 The hypertension and tachycardia caused by ... The use of dibenamine in the diagnosis of a case of pheochromocytoma has recently been described. 9 An adrenolytic drug, 933 F (2-piperidino ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Merck also announced the decision to stop the phase III HYPERION study on its new pulmonary arterial hypertension (PAH ... of patients with advanced pheochromocytoma and paraganglioma.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

ABSTRACT: Pheochromocytoma (PHEO) is a rare endocrine tumor from the chromaffin cells in the adrenomedullary gland and sympathetic/parasympathetic ganglia, secreting ...

ABSTRACT: Pheochromocytoma (PHEO) is a rare endocrine tumor from the chromaffin cells in the adrenomedullary gland and sympathetic/parasympathetic ganglia, secreting ...

Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.